
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
Designed to solve complex downstream separation and purification challenges for many biotherapeutic modalities, a suite of hydrophobic chromatography resins (POROS HIC) has been developed that cover a wide range of hydrophobicity.







